Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland
- PMID: 18573832
- DOI: 10.1177/1352458508090663
Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland
Abstract
Background: Northern Ireland is recognized as an area of high risk for multiple sclerosis. The original study of Allison and Millar in 1951 found a prevalence of 51/100,000 and mean annual incidence of 2.74/100,000/year. Subsequent studies in 1961, 1986, and 1996 suggested rising prevalence--80, 138, and 168.2/100,000, respectively.
Methods: In 2004, we surveyed the North-East of Northern Ireland (population 160,446, area 2030 km(2)) using multiple sources of case ascertainment, all satisfying the Poser criteria for definite or probable multiple sclerosis (MS) or the McDonald criteria.
Results: From a provisional list of 469 cases, 370 (123 males, 247 females) were identified. The prevalence was 230.6 per 100,000 (95% CI 207.0-255.4) with significantly higher prevalence in females (300.8/100,000) than males (157.0/100,000). Direct standardization to the 1961 Northern Ireland population reduced the overall prevalence rate to 200.5/100,000 (95% CI 193.2-208.0), in females to 270.2/100,000 (95% CI 258.8-282.4) and in males to 131.1/100,000 (95% CI 122.8-139.9). In 1996, incidence had risen to 9.3/100,000/year (14 cases in population of 151,000) with a higher incidence in females (10.3/100,000/year) than males (8.3/100,000/year).
Conclusions: Northern Ireland continues to have a rising prevalence of MS. The increase in incidence suggests a true increase in the disease.
Similar articles
-
Possible increasing risk of multiple sclerosis in Catania, Sicily.Neurology. 2005 Oct 25;65(8):1259-63. doi: 10.1212/01.wnl.0000180628.38786.85. Neurology. 2005. PMID: 16247054
-
Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan.Neurology. 2007 Sep 18;69(12):1224-9. doi: 10.1212/01.wnl.0000276991.13764.77. Neurology. 2007. PMID: 17875910
-
An epidemiologic study of multiple sclerosis in Northern Ireland.Neurology. 1998 Feb;50(2):423-8. doi: 10.1212/wnl.50.2.423. Neurology. 1998. PMID: 9484366
-
The prevalence of multiple sclerosis in the Middle East.Neuroepidemiology. 2008;31(2):129-37. doi: 10.1159/000151514. Epub 2008 Aug 21. Neuroepidemiology. 2008. PMID: 18716409 Review.
-
Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function.Mult Scler. 2007 Aug;13(7):827-39. doi: 10.1177/1352458507077174. Mult Scler. 2007. PMID: 17881396 Review.
Cited by
-
Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil.BMC Neurol. 2022 Aug 17;22(1):301. doi: 10.1186/s12883-022-02820-0. BMC Neurol. 2022. PMID: 35978300 Free PMC article.
-
Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol. 2019 Mar;18(3):269-285. doi: 10.1016/S1474-4422(18)30443-5. Epub 2019 Jan 21. Lancet Neurol. 2019. PMID: 30679040 Free PMC article.
-
The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis.Int J Mol Sci. 2019 Jan 14;20(2):303. doi: 10.3390/ijms20020303. Int J Mol Sci. 2019. PMID: 30646507 Free PMC article. Review.
-
The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis.Toxins (Basel). 2019 Mar 5;11(3):147. doi: 10.3390/toxins11030147. Toxins (Basel). 2019. PMID: 30841532 Free PMC article. Review.
-
Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.Ir J Med Sci. 2011 Jun;180(2):337-41. doi: 10.1007/s11845-011-0685-5. Epub 2011 Feb 4. Ir J Med Sci. 2011. PMID: 21293948 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical